Nutritional treatment for inborn errors of metabolism: Indications, regulations, and availability of medical foods and dietary supplements using phenylketonuria as an example

详细信息    查看全文

• 作者：Kathryn M. Camp ; Michele A. Lloyd-Puryear ; Kathleen L. Huntington
• 关键词：IEM ; inborn error of metabolism ; HHS ; Health and Human Services ; PKU ; phenylketonuria ; Phe ; phenylalanine ; Tyr ; tyrosine ; DRI ; Dietary Reference Intake ; FDA ; Food and Drug Administration ; CMS ; Centers for Medicare and Medicaid Services ; HCPCS ; Healthcare
• 刊名：Molecular Genetics and Metabolism
• 出版年：2012
• 出版时间：September-October, 2012
• 年：2012
• 卷：107
• 期：1-2
• 页码：3-9
• 全文大小：194 K

文摘

Medical foods and dietary supplements are used to treat rare inborn errors of metabolism (IEM) identified through state-based universal newborn screening. These products are regulated under Food and Drug Administration (FDA) food and dietary supplement statutes. The lack of harmony in terminology used to refer to medical foods and dietary supplements and the misuse of words that imply that FDA regulates these products as drugs have led to confusion. These products are expensive and, although they are used for medical treatment of IEM, third-party payer coverage of these products is inconsistent across the United States. Clinicians and families report termination of coverage in late adolescence, failure to cover treatment during pregnancy, coverage for select conditions only, or no coverage. We describe the indications for specific nutritional treatment products for IEM and their regulation, availability, and categorization. We conclude with a discussion of the problems that have contributed to the paradox of identifying individuals with IEM through newborn screening but not guaranteeing that they receive optimal treatment. Throughout the paper, we use the nutritional treatment of phenylketonuria as an example of IEM treatment.